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People over 65 years of age constitute over 80% of patients with heart failure (HF) and 
the incidence of HF is 10 per 1,000 in people aged above 65 years. Approximately 25% 
of older patients with HF exhibit evidence of frailty. Frail patients with cardiovascular disease 
(CVD) have a worse prognosis than non-frail patients, and frailty is an independent risk 
factor for incident HF among older people. Planning the treatment of individuals with HF 
and concomitant frailty, one should consider not only the limitations imposed by frailty 
syndrome (FS) but also those associated with the underlying heart disease. It needs to 
be emphasized that all patients with HF and concomitant FS require individualized treatment.
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INTRODUCTION
Frailty is defined as a multidimensional physiological syndrome, which mainly occurs in people 
aged above 65  years. It is connected with a significant decrease of physiological reserve caused 
by numerous co-morbidities, influence of stressors, and in general the failure of homeostasis. 
It is the result of both the processes taking place within the body and the influence of the 
external environment on human organism. This finally leads to losses of energy, physical and 
cognitive ability, and health. One of the important factors determining the emergence and 
manifestation of this syndrome is the reduced physiological reserve of the body (Xue, 2011).
Frailty is a geriatric syndrome meeting at least three of five criteria: weakness (low grip 
strength), slowness (decreased walking speed), low level of physical activity, exhaustion, and 
unintentional weight loss (Fried et al., 2001; Clegg et  al., 2013). It is caused by multisystem 
dysregulations, impaired homeostasis, decreased physiologic reserve, and increased risk of 
morbidity and mortality (Morley, 2015).
Although several definitions of frailty have been proposed, there is still not a single acceptable 
definition of this condition. One of the first, introduced by Fried and Walston, is that it is 
“physiological syndrome, characterized by a decrease in the reserves and resistance to stressors 
resulting from the accumulation of reduced capacity of various physiological systems, which 
in turn leads to susceptibility to adverse effects” (Fried and Walston, 2003). Another definition 
of frailty described this syndrome as a “loss of physiological reserve, combined with endocrine 
disruption and dysfunction of the immune system” (Rockwood et  al., 2007).
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Two systematic reviews of 21 studies, including 61,500 of 
the elderly, showed a frailty prevalence of 4.0–59.1% (Collard 
et  al., 2012; Jha et  al., 2015). Based on criteria proposed by 
Fried et  al. (2001), it is estimated that 6.9% of the seniors’ 
population are frail.
It is important to discuss the role of sarcopenia, malnutrition, 
and cognitive impairment (CI) in frailty. A 3-year prospective 
observational study by Tamura et  al. (2018) showed that the 
prevalence of frailty and CI increased with aging, whereas 
the prevalence of sarcopenia is increasing on the plateau after 
the age of 80. Also, no significant differences were noted in the 
prevalence of frailty, CI, and sarcopenia between groups differing 
in terms of coexisting comorbidities (diabetes, hypertension, or 
hyperlipidemia), with some exceptions, possibly due to high risk 
individuals with coexisting cardiovascular diseases (CVD).
The study by Gingrich et  al. (2019) showed that sarcopenia, 
frailty, cachexia, and malnutrition were present in 42, 33, 32, 
and 15% of the patients, respectively (63% had at least one 
syndrome). These syndromes are characterized by significant 
weight loss over the last year, which was most evident in 
malnutrition patients and least noticeable in frail patients, as 
well as in those with significantly reduced physical performance. 
It should be emphasized that, according to the newest findings, 
frail subjects with malnutrition-sarcopenia syndrome (MSS) 
or malnutrition risk and sarcopenia are at increased risk of 
long-term all-cause mortality (Hu et  al., 2017).
Frailty was shown to occur frequently in patients with HF 
with the prevalence ranging from 15 to 74%, depending on 
the studied population and the method of assessment (Altimir 
et  al., 2005; Lupón et  al., 2008; McNallan et  al., 2013). Its 
prevalence increases significantly with age, from 3.2% in patients 
at age 65–70  years to 23.1% among patients 90  years and 
older (Fried et al., 2001; Newman et al., 2001; Jha et al., 2015). 
The recent FRAIL-HF study suggests that frailty may affect 
more than 70% of heart failure (HF) patients over 80  years 
of age (Vidán et  al., 2014; Ponikowski et  al., 2016).
It is been observed that there is a high rate of comorbidities, 
hospitalizations, and deaths in frailty-affected HF patients. 
Chronic HF is associated with a higher risk of adverse events, 
including falls, hospitalizations, and deaths, and then with 
worse prognosis in these patients (Jha et  al., 2015).
There are few frailty assessment scales available to 
objectively evaluate the level of the symptoms and its changes 
over time. Patients with a high frailty score will benefit from 
continuous contact with the HF specialist team, more frequent 
follow-up, and monitoring and individualized self-care support 
(Ponikowski et  al., 2016).
The recommendations of the European Society of Cardiology 
(ESC), the American Heart Association (AHA), and the Society 
for Geriatric Cardiology (SGC) emphasize the importance of 
awareness of the frailty syndrome (FS) in the treatment of 
patients with HF (Alexander et al., 2007; Ponikowski et al., 2016).
THE PATHOGENESIS OF FRAILTY
Pathophysiological mechanisms include chronic inflammation 
and immune activation, with elevated levels of interleukin-6, 
C-reactive protein, tumor necrosis factor-α, neopterin, and 
other substances. Increased counts of white blood cells 
and impaired differentiation of T cells can be  observed 
(Bellumkonda et  al., 2017).
Chronic inflammation has detrimental effects on 
musculoskeletal and endocrine systems, causes anemia, and 
nutritional dysregulation. Skeletal muscles weakness is mainly 
caused by sarcopenia, muscular atrophy, changes in α-motor 
neurons, poor nutrition, growth hormone production, decreased 
sex hormone and insulin-like growth factor 1 levels, and 
decreased physical activity (Narici and Maffulli, 2010). Impaired 
skeletal muscle strength also contributes to osteopenia and 
osteoporosis leading to pathological fractures. Important element 
of frailty is also central nervous system involvement (Hogrel 
et  al., 2015). It can be  caused by vascular damage, blood-brain 
barrier dysfunction and leucoaraiosis, leading to cognitive 
impairment and depression. The term “cognitive frailty” was 
recently described as impaired executive function, balance 
disturbances, falls, functional decline, urge incontinence, and 
disability (Woods et  al., 2013). The above changes are 
accompanied by loss of appetite, malnutrition, nutritional 
deficiencies, and weight loss (Goisser et  al., 2016).
All the above changes are activated by complex multifactorial 
causes, including genetic and metabolic factors, environmental 
stressors, and acute and chronic diseases, common in advanced 
age. They all act as vicious circles accelerating the progress 
of mental and physical impairment and disability (Fried et  al., 
2001). On the other hand, progressing frailty causes exhaustion 
of compensatory mechanisms and decreases resistance to 
stressors, infections, and neoplasms, leading to increased 
morbidity and mortality (Chen et  al., 2014).
DEFINITIONS OF FRAILTY AND 
ASSESSMENT TOOLS
Frailty is a syndrome leading to adverse outcomes in older 
people such as disability in activities in daily living (ADL) 
(Boyd et  al., 2005; Gobbens et  al., 2012), hospitalization (Fried 
et  al., 2001), nursing home placement (Kojima, 2018), falls 
(Fried et  al., 2001), and mortality (Shamliyan et  al., 2013). In 
addition, frailty is associated with a lower quality of life among 
older people (Kojima et  al., 2016). This figure is influenced 
by different characteristics of the sample: the mean age of the 
participants, the ratio between men and women, and the setting 
where the sample is located. In addition, the prevalence of 
frailty depends on the approach of frailty (Collard et al., 2012). 
In general, two approaches of frailty can be  distinguished, an 
Abbreviations: ADHF, Acute decompensated heart failure; ADL, Activities in daily 
living; AHA, American Heart Association; CHS, Cardiovascular Health Study; CI, 
Cognitive impairment; CSHA, Canadian Study of Health and Aging; CVD, 
Cardiovascular disease; ESC, European Society of Cardiology; FS, Frailty syndrome; 
HF, Heart failure; HFpEF, Heart failure with preserved ejection fraction; HFrEF, 
Heart failure with reduced ejection fraction; MSS, Malnutrition-sarcopenia 
syndrome; SASP, Senescence-associated secretory phenotype; SGC, Society for 
Geriatric Cardiology; TFI, Tilburg Frailty Indicator.
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unidimensional and a multidimensional approach. The 
unidimensional approach considers frailty as a physical problem. 
The definition by Fried et  al. (2001) expresses this approach 
of frailty well: “Frailty is a biological syndrome of decreased 
reserve and resistance to stressors, resulting from cumulative 
declines across multiple physiologic systems, causing vulnerability 
to adverse outcomes” (Fried et  al., 2001).
The multidimensional approach of frailty includes not only 
physical problems but also psychological and social problems 
that older people can encounter. An example of a definition 
that fits well the multidimensional approach of frailty is as 
follows: “Frailty is a dynamic state affecting an individual who 
experiences losses in one or more domains of human functioning 
(physical, psychological, social), which is caused by the influence 
of a range of variables and which increases the risk of adverse 
outcomes” (Gobbens et  al., 2010a).
In line with these two different approaches of frailty, several 
operational definitions and measurement instruments have been 
developed. The Cardiovascular Health Study (CHS) Phenotype 
of Frailty instrument assesses only physical frailty (Fried et  al., 
2001). It contains five components: unintentional weight loss, 
weakness (decreased grip strength), poor self-reported endurance, 
slow gait speed, and low physical activity (Fried et  al., 2001). 
According to Fried et  al. (2001), a person is pre-frail as one 
or two of the components are present and a person is referred 
to as frail as at least three of five components of the Phenotype 
of Frailty are present. Many frailty studies have used this 
instrument for identifying frail older people. Another widely 
used frailty instrument is the frailty index (FI), which has 
been developed by Mitnitski et  al. (2001) and is based on the 
Canadian Study of Health and Aging (CSHA) Cumulative 
Deficit Model.
The FI assesses physical, psychological, and social frailty 
components and also diseases and items referring to disability 
in ADL. A relatively new frailty instrument is the Tilburg 
Frailty Indicator (TFI) (Gobbens et  al., 2010c); this instrument 
is based on an integral conceptual model of frailty (Gobbens 
et al., 2010b). As well as the FI, the TFI uses a broad approach 
of frailty. A recent systematic review by Sutton et  al. (2016) 
showed that the TFI has the most robust evidence of reliability 
and validity among 38 frailty assessment tools.
In a systematic review and meta-analysis, Denfeld et  al. 
(2017) found that frailty affects almost half of people with 
heart failure. The prevalence was 42.9% among studies using 
an unidimensional (physical) approach of frailty and slightly 
higher (47.4%) among studies using a multidimensional approach 
of frailty. Older people with HF have a higher risk of adverse 
outcomes such as rehospitalizations (Uchmanowicz et al., 2018) 
and mortality (Cacciatore et  al., 2005). So, the assessment of 
frailty in this high-risk group is an emergent research priority.
The most commonly used frailty instrument among people 
with HF was the Phenotype of Frailty (Fried et al., 2001) (n = 8), 
including modified versions, followed by the Comprehensive 
Geriatric Assessment (CGA) (Rubenstein et  al., 1989) (n  =  4) 
and the FI by Mitnitski et  al. (2001) (n  =  2) (McDonagh et  al., 
2018). The aforementioned TFI is so far used in two studies 
conducted in Poland (Uchmanowicz et al., 2018), demonstrating 
that social frailty adversely affects the ability to self-care in 
older people with heart failure. According to McDonagh et  al. 
(2018) assessment of frailty with a validated instrument as part 
of a holistic treatment plan for older people with HF should 
be  considered.
It is important to identify a frailty measure that will 
be  suitable for clinical and/or research setting. Nowadays, 
there are a lot of methods for measuring frailty. The 
determination of which measurement is most appropriate for 
clinical and/or research applications is currently the subject 
of intense debate. Theoretically, there is a wide range of tools, 
such as the Frailty Phenotype, the Deficit Accumulation Index, 
the Tilburg Frailty Indicator, the Frailty Staging System, the 
Italian Frailty Index, the Canadian Health and Ageing Clinical 
Frailty Scale, and the Survey of Health, Ageing and Retirement 
in Europe Frailty Index. In addition, the Multidimensional 
Prognostic Index (MPI) in HF patients may be  useful 
(Uchmanowicz et  al., 2015; Dent et  al., 2016). The fact is 
that there is an increasing interest in the assessment of frailty, 
but, to date, there is no frailty instrument validated specifically 
in the HF population (McDonagh et  al., 2018). Also, frailty 
and fatigue in HF patients can be  measured with many scales 
but the truth is that none of them have been validated and 
standardized, which seriously preclude a comparative analyses 
and big data research.
FRAILTY AND HEART FAILURE
People over 65  years of age constitute over 80% of patients 
with HF, and the incidence of HF is 10 per 1,000  in people 
aged above 65  years (Go et  al., 2013). Approximately 25% of 
older patients with HF exhibit evidence of frailty (Boxer et  al., 
2008; Dodson and Chaudhry, 2012). Frail patients with CVD 
have a worse prognosis than non-frail patients, and frailty is 
an independent risk factor for incident HF among older people 
(Shinmura, 2016).
Patients with HF are more susceptible to falls and cognitive 
impairment because of reduced cerebral perfusion, which 
accelerates the development of frailty and disability (Singh 
et  al., 2014). Frailty is a strong predictor of mortality, 
rehospitalization, and impaired quality of life in patients with 
chronic HF (Singh et  al., 2014; Uchmanowicz et  al., 2014).
Frailty implies a reduced ability to tolerate biological stressors. 
The condition is associated with circulating inflammatory 
cytokines and sarcopenia, features that are shared with HF 
(Bellumkonda et  al., 2017). Both frailty and HF are associated 
with a proinflammatory phenotype, and frailty is most highly 
associated with cardiovascular dysfunction (Fedarko, 2011; 
Nadruz et  al., 2017). Bellumkonda et  al. (2017) suggest that 
end-organ disease such as HF exacerbates frailty. It was found 
that in community-dwelling individuals, moderate and severe 
frailty have an increased risk of incident HF diagnosis (Khan 
et  al., 2013). Reeves et  al. (2016) found that frailty is more 
common with acute decompensated heart failure (ADHF) as 
compared to those with chronic stable preserved ejection 
fraction (HFpEF) and reduced ejection fraction (HFrEF). 
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Frailty is promoted by chronic underlying skeletal muscle 
changes from long-standing HF (Puthucheary et  al., 2013; 
Kitzman et  al., 2014).
HF is associated with cellular perturbations, which suggests 
that HF could be  considered as an accelerated form of aging 
(Dutta et al., 2012; Wohlgemuth et al., 2014). Although patients 
with symptomatic HF often have cellular and molecular alterations 
in muscle cell composition, these changes slightly differ from 
those of normal aging and inflammatory processes. The changes 
in skeletal muscle in patients with HF are complex and site-
specific and are similar to a mixture of chronic deconditioning 
and inflammation (Goldwater and Pinney, 2015). It is possible 
that the processes that underlie both frailty and HF could 
each perturb homeostasis to lead to low-level chronic 
inflammation (Bellumkonda et  al., 2017).
Chronic inflammatory markers are associated with frailty 
(Darvin et  al., 2014). Sterile inflammation occurs also in 
conditions such as acute ischemia-reperfusion injury or 
during chronic inflammatory processes evident with HF 
(Shen et  al., 2013).
Aging in humans has been associated with increased, low 
levels of circulating pro-inflammatory cytokines (Tracy, 2003; 
De Martinis et  al., 2006). Sterile inflammation may result 
from the breakdown of tissues, such as adipose, skeletal muscle, 
or cardiomyocytes, whereas chronic, indolent viral infections 
(e.g., cytomegalovirus) can also lead to chronic inflammation. 
This may be  exacerbated in HF as increased intravascular 
pressure may result in intestinal congestion, abdominal 
discomfort, and appetite loss, which may lead to cachexia 
(Valentova et  al., 2016).
The pathobiologies of frailty and HF share several common 
pathways, particularly a consistent correlation with inflammatory 
biomarkers (Afilalo et  al., 2014; Uchmanowicz et  al., 2014; 
Goldwater and Pinney, 2015). Frailty is associated with increased 
circulating of TNF-α, IL-6, IFN-γ, and CRP, and these mediators 
are also elevated in HF patients (Kalogeropoulos et  al., 2010; 
Mann, 2015). This suggests that there could be  shared 
inflammatory pathways that are activated by HF and frailty 
(Bellumkonda et  al., 2017). In addition, immune cells and 
cytokines, which are known to exert detrimental effects on 
the arterial wall by promoting atherosclerosis and vascular 
senescence, also accelerate the aging process and impact body 
composition, thereby promoting frailty (Afilalo et  al., 2014; 
Uchmanowicz et  al., 2014; Goldwater and Pinney, 2015).
Chronic inflammation and associated vascular dysfunction 
have also recently been linked to HFpEF (Glezeva et  al., 2015; 
Franssen et  al., 2016), the most common form of HF in the 
older adults (Upadhya et  al., 2015). Systemic inflammation 
can also accelerate skeletal muscle apoptosis and promote 
sarcopenia (Muscaritoli et  al., 2010), and this could enhance 
immobility and cachexia associated with both HF and frailty 
(Bellumkonda et  al., 2017).
Senescent cells that have acquired a senescence-associated 
secretory phenotype (SASP) can as well cause local and potentially 
systemic inflammation. SASP might be  a key phenomenon in 
the association between cellular senescence and the development 
of age-related CVD and (Shinmura, 2016).
DNA damage, impaired autophagy, and mitochondrial 
dysfunction are biological processes that occur in both aging 
and HF, and these processes can lead to metabolic dysfunction, 
cellular senescence, and ultimately cellular necrosis, leading 
to activation of innate immunity and the production of 
inflammatory mediators into the circulation. The protein 
STAT3 limits redox stress and promotes mitochondrial 
function, and mice lacking STAT3 have increased 
proinflammatory cytokines and cardiac fibrosis with age 
(Jacoby et  al., 2003; Bellumkonda et  al., 2017). Aged mice 
deficient in the NLRP3 inflammasome exhibit enhanced walk 
distance and running time as compared to their wild-type 
controls, suggesting that NLRP3 may enhance inflammation 
that leads to frailty (Youm et al., 2013), and there is emerging 
evidence of NLRP3 activation in HF patients (Butts et  al., 
2015). Bellumkonda et  al. (2017) suggest that the NLRP3 
inflammasome may be  a common pathway by which frailty 
and HF interact.
A potential unifying model for a common pathophysiological 
pathway between frailty and HF may be  as well impaired 
mitophagy and mitochondrial dysfunction within cardiomyocytes 
and skeletal muscle, causing cell death and activation of innate 
immunity to induce chronic, low-grade systemic inflammation 
(Bellumkonda et  al., 2017).
Summarizing, HF is related to an anabolic-catabolic imbalance 
in which adaptive neurohormonal mechanisms and autonomic 
nervous activation fail (Afilalo et al., 2014; Uchmanowicz et al., 
2014). In addition to the upregulation of inflammatory cytokines, 
abnormalities in the GH/IGF-1 axis, cortisol regulation, and 
insulin resistance are frequently observed in HF-related frailty 
(Afilalo et  al., 2014; Uchmanowicz et  al., 2014). However, 
frailty might predispose to myocardial damage by reducing 
resistance to stressors such as myocardial ischemia, pressure 
and volume overload, and arrhythmias, subsequently leading 
to decompensation and hospitalization (Afilalo et  al., 2014; 
Singh et  al., 2014).
CLINICAL CONSEQUENCES OF FRAILTY 
AND HEART FAILURE
HF has become one of the biggest challenges of modern 
cardiology. This is primarily a consequence of a constant increase 
in the incidence of HF in developed countries, which is in 
turn associated with population aging. According to current 
estimates, in 2050, more than 40% of Western Europeans will 
be  older than 60  years (Christensen et  al., 2009). As the 
incidence of FS also increases with age, a growing number of 
HF patients will likely present with concomitant FS.
Frailty is considered one of the most important issues related 
to human aging and has significant implications for both 
patients and healthcare systems (Fried et  al., 2001). Published 
evidence shows that frailty is associated with increased risk 
of falling, loss of functional independence, worse quality of 
life, more frequent institutionalization, and higher mortality 
(Boyd et  al., 2005; Puts et  al., 2005; Ensrud et  al., 2007; 
Al Snih et  al., 2009; Chang et  al., 2012; Gale et  al., 2014).
Uchmanowicz et al. Frailty in Heart Failure
Frontiers in Physiology | www.frontiersin.org 5 July 2019 | Volume 10 | Article 791
FS not infrequently imposes physical limitations in the 
activities of daily living, such as bathing or dressing. Furthermore, 
concomitant frailty may mask early manifestations of HF. 
A walking distance or other objective measures of physical 
performance can be  hardly determined in a frail person who 
does not undertake any physical activity. Additionally, the 
physical inactivity may contribute to a progressive cardiac 
damage, which is either not accompanied by severe clinical 
symptoms or manifests atypically. This may result in a diagnostic 
and therapeutic delay, and in some cases, an appropriate therapy 
may be  even implemented too late.
Problems with self-care and limited mobility may hinder 
access of frail persons to healthcare resources, which may result 
in an inadequate control of therapeutic outcomes and cause 
a delay in treatment modifications (Renne and Gobbens, 2018).
The quality of life of both HF patients and frail persons 
is generally low. Multimorbidity, as well as physical, psychological, 
and social components of frailty, were shown to exert a negative 
effect on the quality of life (Fortin et  al., 2004; de Nóbrega 
et  al., 2009; Bilotta et  al., 2010). It is estimated that nearly 
half of persons from general population suffer from at least 
one chronic disease. The most common chronic conditions 
are arthritis, diabetes mellitus, cardiovascular diseases, cancer, 
and stroke (Renne and Gobbens, 2018). Many people, especially 
those aged 65 years or older, present with two or more chronic 
diseases at a time. The multimorbidity is associated with more 
frequent hospitalizations and emergency department visits, as 
well as with worse quality of life (van den Bussche et  al., 
2011; Mujica-Mota et  al., 2015). Available evidence suggests 
that multimorbidity is more common among women than in 
men (Renne and Gobbens, 2018).
To minimize the impact of aging, people should maintain 
adequate physical performance and fitness, inter alia through 
appropriate planning of their physical activity.
THERAPEUTIC CONCEPTS IN FRAILTY 
ASSOCIATED WITH HEART FAILURE
Planning the treatment of individuals with HF and concomitant 
frailty, one should consider not only the limitations imposed 
by FS but also those associated with the underlying heart disease.
Frailty can be  defined as a physical phenotype (Fried et  al., 
2001) or a multidimensional concept, which does not refer 
merely to physical functioning but also expands on psychological 
and social wellbeing. These two distinct concepts of frailty 
were also reflected in the instruments used to assess the severity 
of this condition, as well as in a multidisciplinary approach 
to its management. The phenotype of frailty is a good example 
of the first approach (Fried et  al., 2001). The approach to FS 
will have a substantial impact on patient management.
Recently, a special emphasis is put on the individualization 
of HF management. This tailor-made approach seems to 
be particularly important for some specific patient populations, 
among them persons presenting with concomitant FS.
Since FS is frequently diagnosed in older persons who 
present with multiple comorbidities, problems with self-care, 
and cognitive disorders, its management can be  challenging. 
HF patients with concomitant FS require more attention than 
those without. The problem seems to be  even more complex, 
since according to literature, the vast majority (over 70%) of 
patients with HF and concomitant frailty are older than 80 years 
(Azad and Lemay, 2014).
The authors of the 2016 ESC guidelines for the diagnosis 
and treatment of HF emphasized that patients with concomitant 
FS may benefit more if they are managed by specialized 
multidisciplinary teams, monitored on a regular basis, and 
provided with an individualized support in self-care (Ponikowski 
et  al., 2016). Aside from being managed by cardiologists, HF 
patients with concomitant FS should also receive a complex 
support from nurses, rehabilitation specialists, psychologists 
and, in selected cases, also social workers. Thus, the therapeutic 
plan should extend well beyond a medical consultation. Since 
many older persons have limited access to specialist medical 
care, a key role in the therapeutic process should be  played 
by primary physicians who know their patients well and may 
respond promptly to any changes in their health status.
While the diagnosis of frailty in HF has been a subject of 
many previous studies, published data about the interventions 
in frailty are quite limited. It needs to be  emphasized that all 
patients with HF and concomitant FS require individualized 
treatment. However, a few key common areas can be  identified 
that seem to be  vital for the management of this group:
 1. Improvement of social support, especially support in self-
care, which also includes control of treatment adherence. 
The character of social support covers many aspects of daily 
functioning with HF, including quality of the relationship, 
caring for the person, practical issues, and emotional support, 
ensuring information support. It was shown that the level 
of perceived social support was largely related to the overall 
self-care of HF patients. This mainly concerned specific 
self-care behaviors such as contact with a healthcare 
professional to report weight gain, reduced fluid intake, take 
medication, take fluid injections, and exercise regularly. All 
these activities are essential elements in the self-care of HF 
patients, in particular, the adherence to medication, which 
is a key behavior in the treatment of HF and prevention 
of admission to hospital (Gallagher et  al., 2011). Moreover, 
measures of physical frailty and social support improve 
prediction of 30-day outcome after an admission for HF 
(Sokoreli et  al., 2019).
 2. It was observed that frailty, multimorbidity, obesity, and 
decreased physical activity as well as mental health status 
are risk factors for excessive polypharmacy. The Sweden 
cohort study among 1,742,336 older adults demonstrated 
that the mean exposition was 4.6 different drugs with range 
from 4.4 drugs among participants living in the community 
to 8.2  in nursing homes. The baseline polypharmacy (≥5 
drugs) was in 44% and the excessive polypharmacy (≥10 
drugs) was in 12%, while during the follow-up, the incidence 
rate of polypharmacy was 20 and that of excessive 
polypharmacy was 8 per 100 person-years (Morin et al., 2018). 
To avoid excessive polypharmacy with its potentially adverse 
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consequences, doctors should carefully check the 
appropriateness of the drugs used, especially in patients 
with multifactorial diseases, obesity, and frailty (Rieckert 
et  al., 2018). Reduction of polypharmacy (within a safe 
margin) through elimination of medications that are not 
absolutely necessary in the therapeutic process and leaving 
only those which are vital for the control of clinical symptoms. 
Such approach should result in better medication compliance 
and more satisfactory treatment outcomes.
 3. Regular resistance and aerobic exercise. The pivotal role 
of physical activity is currently recognized in many chronic 
diseases, including chronic HF and cancer. Exercise is also 
a key component of management in patients with frailty. 
One study showed that frail persons who participated in 
a resistance training program for 1 year after hip fracture 
less often required hospitalization and nursing home 
admission (Singh et  al., 2012). Published evidence suggests 
that three weekly exercise sessions (each lasting 45–60 min), 
performed for at least 5 months, are enough to produce 
a beneficial effect in older frail adults (Theou et  al., 2011). 
Exercise was shown to improve functional performance of 
frail persons (walking speed, chair stand, stair climbing, 
and balance) and to reduce depression and the fear of 
falling (Morley et  al., 2013). What is most important, the 
exercise should always be  individually assessed and should 
take into consideration the type of training (aerobic/
resistance/flexibility/balance), its frequency (2–5  days per 
week), intensity (low/moderate/vigorous), time (20–60 min 
per day), volume (50–150  min per week), and progression 
(tolerance and preference), as well as maximal oxygen 
consumption (VO2) (Zaleski et  al., 2016). There is strong 
evidence indicating the beneficial effects of exercise in 
elderly which reduce negative symptoms of frailty syndrome, 
falls episodes, disturbed mental health, impaired cognitive 
functions, cardiopulmonary dysfunction, and a wide range 
of musculoskeletal dysfunctions such as balance problems, 
gait disturbances, poor muscular endurance, and functional 
capacity (de Labra et  al., 2015).
 4. An adequate diet including vitamin D supplementation 
if necessary. Weight loss is a major component of FS 
(Landi et  al., 2010). Calorie supplementation was shown 
to enhance weight gain and to reduce morbidity and 
mortality in undernourished older individuals (Milne et al., 
2009). Also, HF is often accompanied by eating 
disorders and the loss of muscle mass, which may eventually 
lead to cachexia. Nowadays, cachexia is defined as 
an unintentional weight loss (without concomitant 
dehydration) of more than 5% within 12  months (or a 
decrease in BMI  <20  kg/m2) and presence of at least 
three of the following criteria: muscle weakness, fatigue, 
anorexia, low fat-free mass index, and abnormal laboratory 
parameters of the blood such as elevated concentrations 
of inflammatory markers (CRP, IL-6), anemia (hemoglobin 
<12 g/dl), and hypoalbuminemia (<3.2 g/dl) (Okoshi et al., 
2017). Cachexia is a systemic process involving most body 
tissues, i.e., fat-free tissues (including skeletal muscles), 
adipose tissue (an energy reservoir), and skeleton 
(whereby it may lead to osteoporosis). Cachexia may 
be  present in up to 5–15% of HF patients, especially 
those with advanced stages of HF with reduced ejection 
fraction (von Haehling and Anker, 2014). HF is also 
frequently accompanied by disorders of calcium-phosphate 
metabolism resulting from secondary hypoparathyroidism 
and vitamin D deficiency, both associated primarily with 
kidney dysfunction. HF patients may also present with 
elevated levels of TNF-α, which may result in inhibition 
of calcitriol and vitamin D synthesis. A decrease in vitamin 
D concentration is associated with enhanced release of 
renin and hence may perpetuate cachexia. Thus, it is not 
surprising that vitamin D supplementation during HF 
treatment gains a growing number of supporters. Research 
showed that aside from the increase in serum concentration 
of vitamin D, the supplementation may also contribute 
to a decrease in the level of aldosterone, a hormone, the 
level of which is usually too high in HF patients 
(Witham et al., 2010; Boxer et al., 2013; Sciatti et al., 2016).
Similar recommendations as those presented above were 
also included in the frailty consensus published by delegates 
from six major international, European and US societies (Morley 
et  al., 2013). Although this document was not addressed 
specifically to HF patients, some data can be safely extrapolated 
on this group. Nevertheless, we need more empirical data about 
the outcomes of various interventions in patients with HF and 
concomitant frailty to develop the management strategies that 
would be most beneficial for this specific population. Irrespective 
of the intervention type, the management of frailty in HF 
should extend onto all three domains of human functioning: 
physical, psychological, and social wellbeing.
SUMMARY
HF has become one of the biggest challenges of modern 
cardiology. This is primarily a consequence of a constant increase 
in the incidence of HF in developed countries, which is in 
turn associated with population aging. As the incidence of FS 
also increases with age, a growing number of HF patients will 
likely present with concomitant FS. Special attention should 
be  paid to the specific components of frailty, such as the sense 
of being physically unhealthy, lack of social relations and social 
support, feeling down, and inability to cope with problems, 
since all these elements, as well as the HF itself, have the 
biggest impact on the quality of life (Gobbens et  al., 2017; 
Renne and Gobbens, 2018). Therefore, the recommendations 
of the ESC, the AHA, and the SGC emphasize the importance 
of awareness of the FS in the treatment of patients with heart 
failure (Alexander et  al., 2007).
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